

### DESCRIPTION

- \*ESCIGRESS contains Escitalopram 5 mg, 10 mg, and 20 mg film coated tablets. The single and multiple dose pharmacokinetics of escitalopram are linear and dose-proportional in a dose range of 10 to 30 mg/day.
- ESCIGRESS-CZ contains Escitalopram in combination with Clonazepam in the strengths of 10 mg & 0.25 mg as film coated tablets / 10 mg & 0.5 mg available as film coated scored tablets.

### **Mechanism of action:**

### **₩<u>Escitalopram</u>**:

The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. Escitalopram is at least 100-fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake and inhibition of 5-HT neuronal firing rate.

### **₩<u>Clonazepam:</u>**

The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system.

### **INDICATION:**

Treatment of major depressive disorder.

Panic disorder.

### **DOSAGE:**

### **₩<u>Major Depressive Disorder.</u>**

### Escitalopram:

- The recommended dose of escitalopram is 10 mg once daily. *Clonazepam:*
- The initial dose for adults is 0.25 mg bid.

To reduce the inconvenience of somnolence, administration of one dose at bedtime may be desirable.

### **ADMINISTRATION:**


It comes as film coated tablets and to be taken by mouth.

### **PRESENTATION:**

Available as strip of 10 tablets.

### La Renon Healthcare Pvt Ltd.

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone: + 91-79-3046-1000 (30 lines) Fax: +91-79-3046-1001 E-mail: info@larenon.com | Web: www.larenon.com



# "A Formidable Combination"

ESCITALOPRAM TABLETS 5MG. 10 MG. 20 MG





# ESCITALOPRAM TABLETS WITH CLONAZEPAM 10 MG & 0.25 MG / 10 MG & 0.5 MG

### BACKGROUND: **Anxiety:**

Anxiety is an emotion characterized by feelings of tension, worried thoughts and physical changes like increased blood pressure.

People with anxiety disorders usually have recurring intrusive thoughts or concerns. There are six main type of anxiety disorder

### **#Depression:**

Depression is a common mental disorder, characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness and poor concentration.

It can be long lasting or recurrent, substantially impairing a person's ability to function at work or school, or cope with daily life.

At its most severe, depression can lead to suicide. When mild, depression can be treated without medicines but, when moderate or severe, people may need medication and professional talking treatments.



### PREVALENCE:

- **WHO 2015: 350** million people worldwide suffer from depression and this approximate 5% of world's population<sup>1</sup>.
- \*Depression can lead to suicide. Over 800 000 people die due to suicide every year. Suicide is the second leading cause of death in 15-29-year-olds<sup>1</sup>.
- #Global worldwide prevalence of anxiety disorder ranges from 7.3% to 10. 4%<sup>2</sup>.
- In the year 2013 There were 8.2 million cases of Anxiety reported in the Uk<sup>3</sup>.

<sup>#</sup>Anxiety disorders rank sixth, accounting for 4% of all Years lived in Disability in Europe<sup>4</sup>.

Generalized Anxiety Disorder affects 6.8 million adults, or 3.1% of the U.S. population<sup>5</sup>.

Reference

- 1. WHO Report; 2015 Psychological Medicine; 43 (05): 2013
- UK. Journal of Psychopharmacology, 27(9), pp.761-770
- 4. WHO Europe : Global Health Estimates; 2014
- 5. Anxiety and Depression Association of America, ADAA; 2015

### **CLINICAL EFFECTIVENESS**

### As per Expert Review of Neurotherapeutics: 2008 #<u>1. "Escitalopram for the treatment of major depression"</u>


with Escitalopram (10-20 mg/day) or a comparator for 8 weeks.

Outcome of pooled data analysis suggests that:

- Escitalopram is more efficient than placebo (approximately 57% responders vs 42%).
- ≤ 12).
- appetite and lassitude.

### **#2.** "Escitalopram for the treatment of anxiety"


- Social Anxiety), in CGI and in working and social.
- escitalopram than for placebo (54% v. 39%; P50.01).



Indian Journal of Psychiatry; 2014

Indian Psychiatric Society Multi-Centric Study: Prescription Patterns of Psychotropics in India

- antidepressant in India.
- Clonazepam (64%) is most commonly prescribed benzodiazepine in India.



- controlling depressive symptoms than escitalopram alone.
- disorders.

• Pooled data analysis of six double-blind, placebo-controlled studies in 2279 depressed patients treated

• Escitalopram is superior to placebo (47 vs 34%) in the number of patients who achieved remission (MADRS


• All items of the MADRS scale significantly more reduced by Escitalopram than by placebo except loss of

• Escitalopram at the dose 10-20 mg/day for 12-week-long treatment in 358 patients with social anxiety disorder (SAD) is better in elimination of phobic symptoms and avoidance behavior (Liebowitz scale for

• There are significantly more responders to treatment for escitalopram than for treatment for

Fig. Mean change from baseline in Liebowitz Social Anxiety Scale(LSAS) total score(last observation carried forward; LOCF) by week, for the escitalopram and placebo groups(full analysis set), adjusted for baseline score and centre by least squares mean analysis of covariance(\*\*P<0.01v. placebo).

## • Study on 4480 patient across 11 centers in India suggests that Escitalopram (33.8%) is most prescribed



• Combination of escitalopram with clonazepam provide faster onset of action and is more effective in

• Combination approved by CDSCO for treatment of patients with co-morbid depression and anxiety